New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer
Prostate cancer is the most common cancer in men in the United States, and it is the second leading cause of cancer-related death in American men. The androgen receptor (AR), a receptor of nuclear family and a transcription factor, is the most important target in this disease. While most efforts in...
Saved in:
Main Authors: | Abhijit M. Godbole, Vincent C. O. Njar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Prostate Cancer |
Online Access: | http://dx.doi.org/10.1155/2011/918707 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
by: Kristene Myklak, et al.
Published: (2011-01-01) -
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
by: Manish Kohli, et al.
Published: (2012-01-01) -
Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
by: Lior Z. Braunstein, et al.
Published: (2014-01-01) -
High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy
by: Satoko Kojima, et al.
Published: (2021-01-01) -
Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
by: Renliang Yi, et al.
Published: (2016-01-01)